AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Exploring JAK Inhibitors for T-Cell Lymphoma
Discussion on the potential efficacy of JAK inhibitors beyond Ruxolitinib in treating T-cell lymphoma, highlighting their role in induction and maintenance for T lymphomas. Challenges in studying rare subtypes of T-cell lymphoma and comparison of drug effectiveness in T-cell lymphoma versus myeloproliferative neoplasms are also covered.